A1V Stock Overview
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer.
Aptorum Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.47|
|52 Week High||US$2.28|
|52 Week Low||US$0.86|
|1 Month Change||18.55%|
|3 Month Change||66.10%|
|1 Year Change||-27.94%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-89.50%|
Recent News & Updates
|A1V||DE Biotechs||DE Market|
Return vs Industry: A1V underperformed the German Biotechs industry which returned -2% over the past year.
Return vs Market: A1V underperformed the German Market which returned -20% over the past year.
|A1V Average Weekly Movement||9.8%|
|Biotechs Industry Average Movement||8.7%|
|Market Average Movement||5.7%|
|10% most volatile stocks in DE Market||10.7%|
|10% least volatile stocks in DE Market||2.8%|
Stable Share Price: A1V is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: A1V's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity.
Aptorum Group Fundamentals Summary
|A1V fundamental statistics|
Is A1V overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A1V income statement (TTM)|
|Cost of Revenue||US$1.46m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.70|
|Net Profit Margin||-1,624.64%|
How did A1V perform over the long term?See historical performance and comparison
Is A1V undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A1V?
Other financial metrics that can be useful for relative valuation.
|What is A1V's n/a Ratio?|
Price to Sales Ratio vs Peers
How does A1V's PS Ratio compare to its peers?
|A1V PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
A1V Aptorum Group
Price-To-Sales vs Peers: A1V is expensive based on its Price-To-Sales Ratio (35.7x) compared to the peer average (11x).
Price to Earnings Ratio vs Industry
How does A1V's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: A1V is expensive based on its Price-To-Sales Ratio (35.7x) compared to the German Biotechs industry average (5.8x)
Price to Sales Ratio vs Fair Ratio
What is A1V's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||35.7x|
|Fair PS Ratio||7.5x|
Price-To-Sales vs Fair Ratio: A1V is expensive based on its Price-To-Sales Ratio (35.7x) compared to the estimated Fair Price-To-Sales Ratio (7.5x).
Share Price vs Fair Value
What is the Fair Price of A1V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A1V (€1.47) is trading below our estimate of fair value (€38.07)
Significantly Below Fair Value: A1V is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Aptorum Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A1V is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Earnings vs Market: A1V is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A1V is expected to become profitable in the next 3 years.
Revenue vs Market: A1V's revenue (57% per year) is forecast to grow faster than the German market (4.7% per year).
High Growth Revenue: A1V's revenue (57% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A1V's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Aptorum Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A1V is currently unprofitable.
Growing Profit Margin: A1V is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A1V is unprofitable, and losses have increased over the past 5 years at a rate of 8.9% per year.
Accelerating Growth: Unable to compare A1V's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A1V is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).
Return on Equity
High ROE: A1V has a negative Return on Equity (-154.88%), as it is currently unprofitable.
Discover strong past performing companies
How is Aptorum Group's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A1V's short term assets ($12.7M) exceed its short term liabilities ($4.4M).
Long Term Liabilities: A1V's short term assets ($12.7M) exceed its long term liabilities ($23.9K).
Debt to Equity History and Analysis
Debt Level: A1V is debt free.
Reducing Debt: A1V has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A1V has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A1V has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.8% each year
Discover healthy companies
What is Aptorum Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A1V's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A1V's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A1V's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A1V's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A1V has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Darren Lui (40 yo)
Mr. Darren Lui serves as Executive Director at Aptorum Group Limited since 2022 and also served as President since October 1, 2017 until June 01, 2022 and serves as its Chief Executive Officer since June 0...
CEO Compensation Analysis
Compensation vs Market: Darren's total compensation ($USD512.12K) is about average for companies of similar size in the German market ($USD426.57K).
Compensation vs Earnings: Darren's compensation has increased whilst the company is unprofitable.
Experienced Management: A1V's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: A1V's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.
Aptorum Group Limited's employee growth, exchange listings and data sources
- Name: Aptorum Group Limited
- Ticker: A1V
- Exchange: DB
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$54.983m
- Listing Market Cap: US$54.136m
- Shares outstanding: 35.70m
- Website: https://www.aptorumgroup.com
Number of Employees
- Aptorum Group Limited
- 17 Hanover Square
- Greater London
- W1S 1BN
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/06 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.